Targeting Transcellular Transport of α-Synuclein for Developing Disease-Modifying Therapies for Synucleinopathy Takafumi Hasegawa 1 1Division of Neurology, Department of Neuroscience & Sensory Organs, Tohoku University Graduate School of Medicine Keyword: パーキンソン病 , 多系統萎縮症 , αシヌクレイン , シヌクレイノパチー , プリオン様伝播 , 疾患修飾療法 , Parkinson's disease , multiple system atrophy , α-synuclein , synucleinopathy , prion-like transmission , disease-modifying therapy pp.551-556
Published Date 2018/5/1
DOI https://doi.org/10.11477/mf.1416201037
  • Abstract
  • Look Inside
  • Reference


Parkinson's disease (PD) is the second most common neurodegenerative disorder and it is characterized by progressive physical disability along with a variety of non-motor symptoms. Drugs that replenish dopamine can partly alleviate the motor symptoms; however, they do not cure the disease itself. Therefore, there is an urgent need for disease modifying therapies that would delay or prevent neurodegeneration. Increasing evidence suggests that α-synuclein, a key molecule in PD, is secreted into the extracellular environment and can be transported from cell-to-cell, thereby affecting the physiological state of the neighboring cells in a prion-like manner. Given the potential role of extracellular α-synuclein as the cause of disease progression, its prion-like propagation is a promising target for developing disease-modifying therapies for PD and other synucleinopathies.

Copyright © 2018, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院